NeuroSense Therapeutics Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Herzliya, Israel, seeks to have the registration become effective on May 22, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. NeuroSense Therapeutics has authorized its counsel, Greenberg Traurig, P.A., and specifically Gary Emmanuel, to communicate with the SEC regarding the effectiveness of the Registration Statement and to modify or withdraw the request for acceleration if necessary.

NeuroSense Therapeutics Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Herzliya, Israel, seeks to have the registration become effective on May 22, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. NeuroSense Therapeutics has authorized its counsel, Greenberg Traurig, P.A., and specifically Gary Emmanuel, to communicate with the SEC regarding the effectiveness of the Registration Statement and to modify or withdraw the request for acceleration if necessary.